Type i interferons in viral control and immune regulation

Current Opinion in Virology

Volumn 16, Issue , 2016, Pages 31-40

  Teijaro, John R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GUANOSINE TRIPHOSPHATASE; INSULIN RECEPTOR SUBSTRATE 1; INTERFERON; INTERLEUKIN 10; MAMMALIAN TARGET OF RAPAMYCIN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE 1; STAT1 PROTEIN; STAT2 PROTEIN; VIRUS ANTIBODY; ANTIVIRUS AGENT;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CELL ADHESION; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOREGULATION; INFECTION CONTROL; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MACROPHAGE; MEMORY T LYMPHOCYTE; NATURAL KILLER CELL; NONHUMAN; PERSISTENT INFECTION; PERSISTENT VIRUS INFECTION; PRE B LYMPHOCYTE; PRIORITY JOURNAL; SEASONAL INFLUENZA; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; T LYMPHOCYTE; UPREGULATION; VACCINIA VIRUS; VESICULOVIRUS; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION; ACUTE DISEASE; ANIMAL; CHRONIC DISEASE; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE SUBPOPULATION; VIRUS DISEASES;

ACUTE DISEASE; ANIMALS; ANTIVIRAL AGENTS; CHRONIC DISEASE; HUMANS; IMMUNOMODULATION; INTERFERON TYPE I; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; VIRAL LOAD; VIRUS DISEASES; VIRUS REPLICATION;

EID: 84955242868     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2016.01.001     Document Type: Review

References (106)

1. A. Isaacs, and J. Lindenmann Virus interference. I. The interferon Proc R Soc Lond B Biol Sci 147 1957 258 267
2. A. Isaacs, J. Lindenmann, and R.C. Valentine Virus interference. II. Some properties of interferon Proc R Soc Lond B Biol Sci 147 1957 268 273
3. J.M. Gonzalez-Navajas, J. Lee, M. David, and E. Raz Immunomodulatory functions of type I interferons Nat Rev Immunol 12 2012 125 135
4. F. McNab, K. Mayer-Barber, A. Sher, A. Wack, and A. O'Garra Type I interferons in infectious disease Nat Rev Immunol 15 2015 87 103
5. J. Crouse, U. Kalinke, and A. Oxenius Regulation of antiviral T cell responses by type I interferons Nat Rev Immunol 15 2015 231 242
6. G. Trinchieri Type I interferon: friend or foe? J Exp Med 207 2010 2053 2063
7. G.R. Stark, I.M. Kerr, B.R. Williams, R.H. Silverman, and R.D. Schreiber How cells respond to interferons Annu Rev Biochem 67 1998 227 264
8. L.C. Platanias, and E.N. Fish Signaling pathways activated by interferons Exp Hematol 27 1999 1583 1592
9. J.W. Schoggins, S.J. Wilson, M. Panis, M.Y. Murphy, C.T. Jones, P. Bieniasz, and C.M. Rice A diverse range of gene products are effectors of the type I interferon antiviral response Nature 472 2011 481 485
10. J.W. Schoggins, and C.M. Rice Interferon-stimulated genes and their antiviral effector functions Curr Opin Virol 1 2011 519 525
11. J.D. Farrar, J.D. Smith, T.L. Murphy, and K.M. Murphy Recruitment of Stat4 to the human interferon-alpha/beta receptor requires activated Stat2 J Biol Chem 275 2000 2693 2697
12. N. Torpey, S.E. Maher, A.L. Bothwell, and J.S. Pober Interferon alpha but not interleukin 12 activates STAT4 signaling in human vascular endothelial cells J Biol Chem 279 2004 26789 26796
13. S. Matikainen, T. Sareneva, T. Ronni, A. Lehtonen, P.J. Koskinen, and I. Julkunen Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells Blood 93 1999 1980 1991
14. K.B. Nguyen, W.T. Watford, R. Salomon, S.R. Hofmann, G.C. Pien, A. Morinobu, M. Gadina, J.J. O'Shea, and C.A. Biron Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection Science 297 2002 2063 2066
15. J.E. Darnell Jr., I.M. Kerr, and G.R. Stark Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 264 1994 1415 1421
16. L.C. Platanias Mechanisms of type-I- and type-II-interferon-mediated signalling Nat Rev Immunol 5 2005 375 386
17. E.N. Fish, S. Uddin, M. Korkmaz, B. Majchrzak, B.J. Druker, and L.C. Platanias Activation of a CrkL-stat5 signaling complex by type I interferons J Biol Chem 274 1999 571 573
18. S. Uddin, E.N. Fish, D.A. Sher, C. Gardziola, M.F. White, and L.C. Platanias Activation of the phosphatidylinositol 3-kinase serine kinase by IFN-alpha J Immunol 158 1997 2390 2397
19. S. Uddin, B. Majchrzak, J. Woodson, P. Arunkumar, Y. Alsayed, R. Pine, P.R. Young, E.N. Fish, and L.C. Platanias Activation of the p38 mitogen-activated protein kinase by type I interferons J Biol Chem 274 1999 30127 30131
20. S. Uddin, F. Lekmine, N. Sharma, B. Majchrzak, I. Mayer, P.R. Young, G.M. Bokoch, E.N. Fish, and L.C. Platanias The Rac1/p38 mitogen-activated protein kinase pathway is required for interferon alpha-dependent transcriptional activation but not serine phosphorylation of Stat proteins J Biol Chem 275 2000 27634 27640
21. S. Uddin, B. Majchrzak, P.C. Wang, S. Modi, M.K. Khan, E.N. Fish, and L.C. Platanias Interferon-dependent activation of the serine kinase PI 3′-kinase requires engagement of the IRS pathway but not the Stat pathway Biochem Biophys Res Commun 270 2000 158 162
22. F. Lekmine, S. Uddin, A. Sassano, S. Parmar, S.M. Brachmann, B. Majchrzak, N. Sonenberg, N. Hay, E.N. Fish, and L.C. Platanias Activation of the p70 S6 kinase and phosphorylation of the 4E-BP1 repressor of mRNA translation by type I interferons J Biol Chem 278 2003 27772 27780
23. D.A. Jaitin, L.C. Roisman, E. Jaks, M. Gavutis, J. Piehler, J. Van der Heyden, G. Uze, and G. Schreiber Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta Mol Cell Biol 26 2006 1888 1897
24. E. Kalie, D.A. Jaitin, R. Abramovich, and G. Schreiber An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities J Biol Chem 282 2007 11602 11611
25. E. Jaks, M. Gavutis, G. Uze, J. Martal, and J. Piehler Differential receptor subunit affinities of type I interferons govern differential signal activation J Mol Biol 366 2007 525 539
26. C. Thomas, I. Moraga, D. Levin, P.O. Krutzik, Y. Podoplelova, A. Trejo, C. Lee, G. Yarden, S.E. Vleck, J.S. Glenn, and et al. Structural linkage between ligand discrimination and receptor activation by type I interferons Cell 146 2011 621 632
27. P. Lindahl, I. Gresser, P. Leary, and M. Tovey Enhanced expression of histocompatibility antigens of lymphoid cells in mice treated with interferon J Infect Dis 133 Suppl 1976 A66 A68
28. P. Lindahl, I. Gresser, P. Leary, and M. Tovey Interferon treatment of mice: enhanced expression of histocompatibility antigens on lymphoid cells Proc Natl Acad Sci U S A 73 1976 1284 1287
29. M. Montoya, G. Schiavoni, F. Mattei, I. Gresser, F. Belardelli, P. Borrow, and D.F. Tough Type I interferons produced by dendritic cells promote their phenotypic and functional activation Blood 99 2002 3263 3271
30. E.I. Zuniga, D.B. McGavern, J.L. Pruneda-Paz, C. Teng, and M.B. Oldstone Bone marrow plasmacytoid dendritic cells can differentiate into myeloid dendritic cells upon virus infection Nat Immunol 5 2004 1227 1234
31. N. Sevilla, D.B. McGavern, C. Teng, S. Kunz, and M.B. Oldstone Viral targeting of hematopoietic progenitors and inhibition of DC maturation as a dual strategy for immune subversion J Clin Invest 113 2004 737 745
32. N. Honke, N. Shaabani, G. Cadeddu, U.R. Sorg, D.E. Zhang, M. Trilling, K. Klingel, M. Sauter, R. Kandolf, N. Gailus, and et al. Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus Nat Immunol 13 2012 51 57
33. J.M. Curtsinger, J.O. Valenzuela, P. Agarwal, D. Lins, and M.F. Mescher Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation J Immunol 174 2005 4465 4469
34. G.A. Kolumam, S. Thomas, L.J. Thompson, J. Sprent, and K. Murali-Krishna Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection J Exp Med 202 2005 637 650
35. R.M. Welsh, K. Bahl, H.D. Marshall, and S.L. Urban Type 1 interferons and antiviral CD8 T-cell responses PLoS Pathog 8 2012 e1002352
36. A.K. Pinto, S. Daffis, J.D. Brien, M.D. Gainey, W.M. Yokoyama, K.C. Sheehan, K.M. Murphy, R.D. Schreiber, and M.S. Diamond A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection PLoS Pathog 7 2011 e1002407
37. A. Volz, M. Langenmayer, S. Jany, U. Kalinke, and G. Sutter Rapid expansion of CD8+ T cells in wild-type and type I interferon receptor-deficient mice correlates with protection after low-dose emergency immunization with modified vaccinia virus Ankara J Virol 88 2014 10946 10957
38. S. Srivastava, M.A. Koch, M. Pepper, and D.J. Campbell Type I interferons directly inhibit regulatory T cells to allow optimal antiviral T cell responses during acute LCMV infection J Exp Med 211 2014 961 974
39. K.B. Nguyen, T.P. Salazar-Mather, M.Y. Dalod, J.B. Van Deusen, X.Q. Wei, F.Y. Liew, M.A. Caligiuri, J.E. Durbin, and C.A. Biron Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection J Immunol 169 2002 4279 4287
40. J. Martinez, X. Huang, and Y. Yang Direct action of type I IFN on NK cells is required for their activation in response to vaccinia viral infection in vivo J Immunol 180 2008 1592 1597
41. I. Hwang, J.M. Scott, T. Kakarla, D.M. Duriancik, S. Choi, C. Cho, T. Lee, H. Park, A.R. French, E. Beli, and et al. Activation mechanisms of natural killer cells during influenza virus infection PLoS ONE 7 2012 e51858
42. J. Crouse, G. Bedenikovic, M. Wiesel, M. Ibberson, I. Xenarios, D. Von Laer, U. Kalinke, E. Vivier, S. Jonjic, and A. Oxenius Type I interferons protect T cells against NK cell attack mediated by the activating receptor NCR1 Immunity 40 2014 961 973
43. H.C. Xu, M. Grusdat, A.A. Pandyra, R. Polz, J. Huang, P. Sharma, R. Deenen, K. Kohrer, R. Rahbar, A. Diefenbach, and et al. Type I interferon protects antiviral CD8+ T cells from NK cell cytotoxicity Immunity 40 2014 949 960
44. E.A. Mack, L.E. Kallal, D.A. Demers, and C.A. Biron Type 1 interferon induction of natural killer cell gamma interferon production for defense during lymphocytic choriomeningitis virus infection MBio 2 2011
45. A. Le Bon, G. Schiavoni, G. D'Agostino, I. Gresser, F. Belardelli, and D.F. Tough Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo Immunity 14 2001 461 470
46. Q. Lin, C. Dong, and M.D. Cooper Impairment of T and B cell development by treatment with a type I interferon J Exp Med 187 1998 79 87
47. E.S. Coro, W.L. Chang, and N. Baumgarth Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection J Immunol 176 2006 4343 4351
48. F.C. Rau, J. Dieter, Z. Luo, S.O. Priest, and N. Baumgarth B7-1/2 (CD80/CD86) direct signaling to B cells enhances IgG secretion J Immunol 183 2009 7661 7671
49. W.E. Purtha, K.A. Chachu, Virgin HWt, and M.S. Diamond Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling J Virol 82 2008 10964 10974
50. K. Fink, K.S. Lang, N. Manjarrez-Orduno, T. Junt, B.M. Senn, M. Holdener, S. Akira, R.M. Zinkernagel, and H. Hengartner Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses Eur J Immunol 36 2006 2094 2105
51. G.E. Price, A. Gaszewska-Mastarlarz, and D. Moskophidis The role of alpha/beta and gamma interferons in development of immunity to influenza A virus in mice J Virol 74 2000 3996 4003
52. J.P. Ray, H.D. Marshall, B.J. Laidlaw, M.M. Staron, S.M. Kaech, and J. Craft Transcription factor STAT3 and type I interferons are corepressive insulators for differentiation of follicular helper and T helper 1 cells Immunity 40 2014 367 377
53. A.S. Devasthanam Mechanisms underlying the inhibition of interferon signaling by viruses Virulence 5 2014 270 277
54. U. Muller, U. Steinhoff, L.F. Reis, S. Hemmi, J. Pavlovic, R.M. Zinkernagel, and M. Aguet Functional role of type I and type II interferons in antiviral defense Science 264 1994 1918 1921
55. Y. Nakayama, E.H. Plisch, J. Sullivan, C. Thomas, C.J. Czuprynski, B.R. Williams, and M. Suresh Role of PKR and Type I IFNs in viral control during primary and secondary infection PLoS Pathog 6 2010 e1000966
56. S. Zhou, A.M. Cerny, K.A. Fitzgerald, E.A. Kurt-Jones, and R.W. Finberg Role of interferon regulatory factor 7 in T cell responses during acute lymphocytic choriomeningitis virus infection J Virol 86 2012 11254 11265
57. J.R. Teijaro, C. Ng, A.M. Lee, B.M. Sullivan, K.C.F. Sheehan, M. Welch, R.D. Schreiber, J.C. de la Torre, and M.B. Oldstone Persistent LCMV infection is controlled by blockade of type 1 interferon signaling Science 2013
58. E.B.Y. Wilson, D.H. Elsaesser, H. Herskovitz, J. Deng, J. Cheng, G. Aronow, B. Karp, and C.L.D.G. Brooks Blockade of chronic type I interferon signaling to control persistent LCMV infection Science 2013
59. M.A. Samuel, and M.S. Diamond Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival J Virol 79 2005 13350 13361
60. A.K. Pinto, H.J. Ramos, X. Wu, S. Aggarwal, B. Shrestha, M. Gorman, K.Y. Kim, M.S. Suthar, J.P. Atkinson, M. Gale Jr., and et al. Deficient IFN signaling by myeloid cells leads to MAVS-dependent virus-induced sepsis PLoS Pathog 10 2014 e1004086
61. K.C. Sheehan, H.M. Lazear, M.S. Diamond, and R.D. Schreiber Selective blockade of interferon-alpha and -beta reveals their non-redundant functions in a mouse model of West Nile virus infection PLoS One 10 2015 e0128636
62. M.B. Frieman, J. Chen, T.E. Morrison, A. Whitmore, W. Funkhouser, J.M. Ward, E.W. Lamirande, A. Roberts, M. Heise, K. Subbarao, and et al. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism PLoS Pathog 6 2010 e1000849
63. J.E. Durbin, A. Fernandez-Sesma, C.K. Lee, T.D. Rao, A.B. Frey, T.M. Moran, S. Vukmanovic, A. Garcia-Sastre, and D.E. Levy Type I IFN modulates innate and specific antiviral immunity J Immunol 164 2000 4220 4228
64. L. Cervantes-Barragan, R. Zust, F. Weber, M. Spiegel, K.S. Lang, S. Akira, V. Thiel, and B. Ludewig Control of coronavirus infection through plasmacytoid dendritic-cell-derived type I interferon Blood 109 2007 1131 1137
65. A. Garcia-Sastre, R.K. Durbin, H. Zheng, P. Palese, R. Gertner, D.E. Levy, and J.E. Durbin The role of interferon in influenza virus tissue tropism J Virol 72 1998 8550 8558
66. M.J. Ciancanelli, S.X. Huang, P. Luthra, H. Garner, Y. Itan, S. Volpi, F.G. Lafaille, C. Trouillet, M. Schmolke, R.A. Albrecht, and et al. Infectious disease. Life-threatening influenza and impaired interferon amplification in human IRF7 deficiency Science 348 2015 448 453
67. T. Hermesh, B. Moltedo, T.M. Moran, and C.B. Lopez Antiviral instruction of bone marrow leukocytes during respiratory viral infections Cell Host Microbe 7 2010 343 353
68. I. Koerner, G. Kochs, U. Kalinke, S. Weiss, and P. Staeheli Protective role of beta interferon in host defense against influenza A virus J Virol 81 2007 2025 2030
69. Y. Arimori, R. Nakamura, H. Yamada, K. Shibata, N. Maeda, T. Kase, and Y. Yoshikai Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice Antiviral Res 99 2013 230 237
70. F.G. Hayden, R. Fritz, M.C. Lobo, W. Alvord, W. Strober, and S.E. Straus Local and systemic cytokine responses during experimental human influenza A virus infection. Relation to symptom formation and host defense J Clin Invest 101 1998 643 649
71. S. Davidson, S. Crotta, T.M. McCabe, and A. Wack Pathogenic potential of interferon alphabeta in acute influenza infection Nat Commun 5 2014 3864
72. K.B. Walsh, J.R. Teijaro, P.R. Wilker, A. Jatzek, D.M. Fremgen, S.C. Das, T. Watanabe, M. Hatta, K. Shinya, M. Suresh, and et al. Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus Proc Natl Acad Sci U S A 108 2011 12018 12023
73. C.E. Chalfant, and S. Spiegel Sphingosine 1-phosphate and ceramide 1-phosphate: expanding roles in cell signaling J Cell Sci 118 2005 4605 4612
74. J.G. Cyster Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs Annu Rev Immunol 23 2005 127 159
75. D.S. Im Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors Acta Pharmacol Sin 31 2010 1213 1222
76. J. Rivera, R.L. Proia, and A. Olivera The alliance of sphingosine-1-phosphate and its receptors in immunity Nat Rev Immunol 8 2008 753 763
77. J.R. Teijaro, K.B. Walsh, S. Cahalan, D.M. Fremgen, E. Roberts, F. Scott, E. Martinborough, R. Peach, M.B. Oldstone, and H. Rosen Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection Cell 146 2011 980 991
78. L.R. Shiow CD69 acts downstream of interferon-[alpha]/[beta] to inhibit S1P1 and lymphocyte egress from lymphoid organs Nature 440 2006 540 544
79. D. Marsolais, B. Hahm, K.B. Walsh, K.H. Edelmann, D. McGavern, Y. Hatta, Y. Kawaoka, H. Rosen, and M.B. Oldstone A critical role for the sphingosine analog AAL-R in dampening the cytokine response during influenza virus infection Proc Natl Acad Sci U S A 106 2009 1560 1565
80. J.R. Teijaro, K.B. Walsh, S. Rice, H. Rosen, and M.B. Oldstone Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection Proc Natl Acad Sci U S A 2014
81. B. Hahm, M.J. Trifilo, E.I. Zuniga, and M.B. Oldstone Viruses evade the immune system through type I interferon-mediated STAT2-dependent, but STAT1-independent, signaling Immunity 22 2005 247 257
82. B. Jacquelin, V. Mayau, B. Targat, A.S. Liovat, D. Kunkel, G. Petitjean, M.A. Dillies, P. Roques, C. Butor, G. Silvestri, and et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response J Clin Invest 119 2009 3544 3555
83. S.E. Bosinger, Q. Li, S.N. Gordon, N.R. Klatt, L. Duan, L. Xu, N. Francella, A. Sidahmed, A.J. Smith, E.M. Cramer, and et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys J Clin Invest 119 2009 3556 3572
84. S. Wieland, Z. Makowska, B. Campana, D. Calabrese, M.T. Dill, J. Chung, F.V. Chisari, and M.H. Heim Simultaneous detection of hepatitis C virus and interferon stimulated gene expression in infected human liver Hepatology 59 2014 2121 2130
85. G. d'Ettorre, M. Paiardini, G. Ceccarelli, G. Silvestri, and V. Vullo HIV-associated immune activation: from bench to bedside AIDS Res Hum Retroviruses 27 2011 355 364
86. A. Boasso, and G.M. Shearer Chronic innate immune activation as a cause of HIV-1 immunopathogenesis Clin Immunol 126 2008 235 242
87. O. Manches, and N. Bhardwaj Resolution of immune activation defines nonpathogenic SIV infection J Clin Invest 119 2009 3512 3515
88. S.G. Deeks, and B.D. Walker Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy Immunity 27 2007 406 416
89. A. Saez-Cirion, G. Pancino, M. Sinet, A. Venet, O. Lambotte, and group AEHCs HIV controllers: how do they tame the virus? Trends Immunol 28 2007 532 540
90. R. Dyavar Shetty, V. Velu, K. Titanji, S.E. Bosinger, G.J. Freeman, G. Silvestri, and R.R. Amara PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques J Clin Invest 122 2012 1712 1716
91. A.I. Su, J.P. Pezacki, L. Wodicka, A.D. Brideau, L. Supekova, R. Thimme, S. Wieland, J. Bukh, R.H. Purcell, P.G. Schultz, and et al. Genomic analysis of the host response to hepatitis C virus infection Proc Natl Acad Sci U S A 99 2002 15669 15674
92. L.G. Guidotti, and F.V. Chisari Immunobiology and pathogenesis of viral hepatitis Annu Rev Pathol 1 2006 23 61
93. U. Garaigorta, and F.V. Chisari Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation Cell Host Microbe 6 2009 513 522
94. I. Osokine, L.M. Snell, C.R. Cunningham, D.H. Yamada, E.B. Wilson, H.J. Elsaesser, J.C. de la Torre, and D. Brooks Type I interferon suppresses de novo virus-specific CD4 Th1 immunity during an established persistent viral infection Proc Natl Acad Sci U S A 111 2014 7409 7414
95. C.T. Ng, B.M. Sullivan, J.R. Teijaro, A.M. Lee, M. Welch, S. Rice, K.C. Sheehan, R.D. Schreiber, and M.B. Oldstone Blockade of interferon beta, but not interferon alpha, signaling controls persistent viral infection Cell Host Microbe 17 2015 653 661
96. N.A. de Weerd, J.P. Vivian, T.K. Nguyen, N.E. Mangan, J.A. Gould, S.J. Braniff, L. Zaker-Tabrizi, K.Y. Fung, S.C. Forster, T. Beddoe, and et al. Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1 Nat Immunol 14 2013 901 907
97. Y. Wang, M. Swiecki, M. Cella, G. Alber, R.D. Schreiber, S. Gilfillan, and M. Colonna Timing and magnitude of type I interferon responses by distinct sensors impact CD8 T cell exhaustion and chronic viral infection Cell Host Microbe 11 2012 631 642
98. M.S. Lee, C.H. Park, Y.H. Jeong, Y.J. Kim, and S.J. Ha Negative regulation of type I IFN expression by OASL1 permits chronic viral infection and CD8(+) T-cell exhaustion PLoS Pathog 9 2013 e1003478
99. N.G. Sandler, S.E. Bosinger, J.D. Estes, R.T. Zhu, G.K. Tharp, E. Boritz, D. Levin, S. Wijeyesinghe, K.N. Makamdop, G.Q. del Prete, and et al. Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression Nature 511 2014 601 605
100. L. Azzoni, A.S. Foulkes, E. Papasavvas, A.M. Mexas, K.M. Lynn, K. Mounzer, P. Tebas, J.M. Jacobson, I. Frank, M.P. Busch, and et al. Pegylated interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration J Infect Dis 207 2013 213 222
101. D.M. Asmuth, R.L. Murphy, S.L. Rosenkranz, J.J. Lertora, S. Kottilil, Y. Cramer, E.S. Chan, R.T. Schooley, C.R. Rinaldo, N. Thielman, and et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial J Infect Dis 201 2010 1686 1696
102. M.H. Heim 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end Nat Rev Immunol 13 2013 535 542
103. R. Moreno-Otero Therapeutic modalities in hepatitis C: challenges and development J Viral Hepat 12 2005 10 19
104. M. Sarasin-Filipowicz, E.J. Oakeley, F.H. Duong, V. Christen, L. Terracciano, W. Filipowicz, and M.H. Heim Interferon signaling and treatment outcome in chronic hepatitis C Proc Natl Acad Sci U S A 105 2008 7034 7039
105. J.J. Hubbard, T. Greenwell-Wild, L. Barrett, J. Yang, R.A. Lempicki, S.M. Wahl, D.M. Asmuth, R.L. Murphy, R.B. Pollard, and S. Kottilil Host gene expression changes correlating with anti-HIV-1 effects in human subjects after treatment with peginterferon Alfa-2a J Infect Dis 205 2012 1443 1447
106. D.M. Asmuth, K. Abel, M.D. George, S. Dandekar, R.B. Pollard, and C.J. Miller Pegylated interferon-alpha 2a treatment of chronic SIV-infected macaques J Med Primatol 37 2008 26 30